8.807USD-4.06%Mkt Cap: —P/E: 6.551d ago
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab…
Industry Peers
Biotechnology$139.84BUSDP/E 32.2
$85.11BUSDP/E 20.4
$69.62BUSD
$60.19BUSDP/E 39.1
$45.16BUSDP/E 19.2
$46.01BUSD
$41.76BUSDP/E 66.2
$35.67BUSDP/E 33.2
$32.46BUSDP/E 42.3
$28.53BUSD
$26.14BUSD
$25.79BUSDP/E 16.2
$20.83BUSDP/E 26.3
$19.17BUSDP/E 26.2
$17.03BUSDP/E 20.0
$16.41BUSD
$13.48BUSDP/E 17.1
$13.42BUSDP/E 187.4
$12.87BUSDP/E 264.5
$12.59BUSD
Key Statistics
Company
Market Cap—
Enterprise Value162.35M $
Revenue (TTM)54.53M $
Gross Profit-10.42M $
Net Income (TTM)-43.99M $
Revenue/Share1.022 USD
Last Price8.807 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees67
CountryGB
SectorHealthcare
IndustryBiotechnology
ISINIE00B91XRN20
Valuation
P/E (Trailing)6.55
P/E (Forward)—
PEG—
EV/EBITDA-2.75
EV/Revenue2.98
P/S—
P/B1.55
EPS (TTM)1.34
EPS (Forward)—
52W Range
8.60234% of range9.200
52W High9.200 USD
52W Low8.602 USD
Profitability
Gross Margin-19.11%
Oper. Margin-1850.20%
EBITDA Margin-108.27%
Profit Margin-80.68%
ROE-14.39%
ROA-10.67%
Growth
Revenue Growth-77.10%
Earnings Growth—
Cash Flow & Leverage
Operating CF-60.05M $
CapEx (TTM)—
FCF Margin-99.44%
FCF Yield—
Net Debt-281.20M $
Net Debt/EBITDA4.76
Balance Sheet
Debt/Equity2.44
Current Ratio25.05
Quick Ratio24.72
Book Value/Sh5.544 USD
Cash/Share5.614 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.39.86M
Float35.45M
Insiders22.11%
Institutions93.32%
Technical
SMA 5031.19 (-71.8%)
SMA 20043.43 (-79.7%)
Beta-0.35
S&P 52W Chg20.80%
Avg Vol (30d)54
Avg Vol (10d)114
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—